Cpmc - Mission Bernal Campus
- Type
- Teaching hospital
- Where
- San Francisco, CA
- Medicare CCN
- 050055
- Received
- $366,232 in 34 records, 2024 ($0 general, $366,232 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | Research payment | 34 | $366,232 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Edwards Lifesciences Corporation | 21 | $279,821 | 2024 |
| Intercept Pharma Europe Ltd. | 3 | $43,870 | 2024 |
| E.R. Squibb & Sons, L.L.C. | 3 | $19,981 | 2024 |
| Mirati Therapeutics, Inc. | 2 | $12,974 | 2024 |
| Incyte Corporation | 2 | $7,335 | 2024 |
| Celgene Corporation | 3 | $2,250 | 2024 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 34 | $366,232 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-12-12 | Edwards Lifesciences Corporation | $14,526 | Research payment | Cash or cash equivalent | Partner3 2015-08 | 2024 | |
| 2024-12-09 | Edwards Lifesciences Corporation | $1,815 | Research payment | Cash or cash equivalent | ALLIANCE 2021-05 | 2024 | |
| 2024-12-05 | Edwards Lifesciences Corporation | $9,994 | Research payment | Cash or cash equivalent | The PROGRESS Trial – Continued Access 2021-01-CAP | 2024 | |
| 2024-11-23 | Edwards Lifesciences Corporation | $2,474 | Research payment | Cash or cash equivalent | CLASP IID 2018-07 | 2024 | |
| 2024-11-04 | Edwards Lifesciences Corporation | $37,760 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2024 | |
| 2024-11-04 | Edwards Lifesciences Corporation | $796 | Research payment | Cash or cash equivalent | SM3 Trial 2017-03 | 2024 | |
| 2024-11-01 | Mirati Therapeutics, Inc. | $955 | Research payment | Cash or cash equivalent | KRAZATI Drug, Oncology | A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colore | 2024 |
| 2024-09-26 | Intercept Pharma Europe Ltd. | $26,855 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2024 |
| 2024-09-12 | Edwards Lifesciences Corporation | $40,216 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2024 | |
| 2024-09-12 | Edwards Lifesciences Corporation | $19,872 | Research payment | Cash or cash equivalent | ALLIANCE 2021-05 | 2024 | |
| 2024-09-12 | Edwards Lifesciences Corporation | $4,138 | Research payment | Cash or cash equivalent | Partner3 2015-08 | 2024 | |
| 2024-09-11 | Celgene Corporation | $1,500 | Research payment | Cash or cash equivalent | REBLOZYL Biological, Hematology | Celgene Connect Myeloid Disease Registry | 2024 |
| 2024-08-29 | Edwards Lifesciences Corporation | $9,450 | Research payment | Cash or cash equivalent | The PROGRESS Trial – Continued Access 2021-01-CAP | 2024 | |
| 2024-07-25 | Intercept Pharma Europe Ltd. | $3,000 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2024 |
| 2024-07-18 | Intercept Pharma Europe Ltd. | $14,014 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2024 |
| 2024-06-24 | Edwards Lifesciences Corporation | $14,850 | Research payment | Cash or cash equivalent | ALLIANCE AVIV 2021-05 | 2024 | |
| 2024-06-06 | Edwards Lifesciences Corporation | $14,327 | Research payment | Cash or cash equivalent | The PROGRESS Trial 2021-01 | 2024 | |
| 2024-05-28 | Edwards Lifesciences Corporation | $4,595 | Research payment | Cash or cash equivalent | ALLIANCE 2021-05 | 2024 | |
| 2024-05-24 | Mirati Therapeutics, Inc. | $12,018 | Research payment | Cash or cash equivalent | A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colore | 2024 | |
| 2024-05-15 | Celgene Corporation | $375 | Research payment | Cash or cash equivalent | Revlimid Drug, Hematology | The purpose of the Connect Myeloid disease registry is to provide unique insights into treatment decisions and treatment | 2024 |
| 2024-05-13 | Edwards Lifesciences Corporation | $20,493 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2024 | |
| 2024-05-09 | Edwards Lifesciences Corporation | $30,144 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2024 | |
| 2024-05-09 | Edwards Lifesciences Corporation | $3,476 | Research payment | Cash or cash equivalent | SM3 Trial 2017-03 | 2024 | |
| 2024-04-24 | E.R. Squibb & Sons, L.L.C. | $1,650 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Adjuvant HCC (mono vs placebo) | 2024 |
| 2024-03-25 | Edwards Lifesciences Corporation | $3,422 | Research payment | Cash or cash equivalent | SM3 Trial 2017-03 | 2024 | |
| 2024-03-07 | Incyte Corporation | $3,885 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxo | 2024 | |
| 2024-02-29 | Edwards Lifesciences Corporation | $8,953 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2024 | |
| 2024-02-26 | Edwards Lifesciences Corporation | $3,727 | Research payment | Cash or cash equivalent | Partner3 2015-08 | 2024 | |
| 2024-02-16 | E.R. Squibb & Sons, L.L.C. | $15,172 | Research payment | Cash or cash equivalent | PhIII Stage 3/4 Resectable Mel Adj Rela+Nivo vs Nivo - A Phase 3, Randomized, Double-blind Study of Adjuvant Immunothera | 2024 | |
| 2024-02-01 | Edwards Lifesciences Corporation | $21,353 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2024 | |
| 2024-02-01 | Edwards Lifesciences Corporation | $13,433 | Research payment | Cash or cash equivalent | ALLIANCE 2021-05 | 2024 | |
| 2024-01-31 | Celgene Corporation | $375 | Research payment | Cash or cash equivalent | Revlimid Drug, Hematology | The purpose of the Connect Myeloid disease registry is to provide unique insights into treatment decisions and treatment | 2024 |
| 2024-01-22 | E.R. Squibb & Sons, L.L.C. | $3,159 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Adjuvant Melanoma Stage II B/C Opdivo Mono | 2024 |
| 2024-01-18 | Incyte Corporation | $3,450 | Research payment | Cash or cash equivalent | A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants | 2024 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In San Francisco, CA, county San Francisco County, CA, state California; placed by its city name.
| Measure | Place (city or town) San Francisco, CA | County San Francisco County, CA | State California |
|---|---|---|---|
| Population B01003 | 830,235 | 830,235 | 39,287,377 |
| Population, 2020 census P1 | 873,965 | 873,965 | 39,538,223 |
| Median age B01002 | 40.0 | 40.0 | 37.9 |
| Under 18 B01001 | 13.7% | 13.7% | 22.0% |
| 65 and over B01001 | 17.6% | 17.6% | 15.7% |
| Households B11001 | 363,970 | 363,970 | 13,548,091 |
| Foreign born B05002 | 34.0% | 34.0% | 27.0% |
| Median household income B19013 | $140,970 | $140,970 | $99,122 |
| Median family income B19113 | $171,141 | $171,141 | $113,346 |
| Per capita income B19301 | $92,289 | $92,289 | $49,513 |
| Poverty rate B17001 | 11.2% | 11.2% | 12.0% |
| Unemployment rate B23025 | 6.1% | 6.1% | 6.6% |
| Civilian labor force B23025 | 507,262 | 507,262 | 20,068,466 |
| Mean commute (minutes) B08013 | 30.4 | 30.4 | 28.7 |
| Bachelor's degree or higher B15003 | 60.3% | 60.3% | 37.1% |
| Housing units B25001 | 414,602 | 414,602 | 14,644,735 |
| Owner-occupied B25003 | 38.2% | 38.2% | 55.9% |
| Renters B25003 | 61.8% | 61.8% | 44.1% |
| Median home value B25077 | $1,394,500 | $1,394,500 | $734,700 |
| Median gross rent B25064 | $2,476 | $2,476 | $2,036 |
| White, not Hispanic B03002 | 36.8% | 36.8% | 33.8% |
| Black B03002 | 4.7% | 4.7% | 5.2% |
| Hispanic or Latino B03002 | 16.2% | 16.2% | 40.2% |
| Asian B03002 | 34.9% | 34.9% | 15.3% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in San Francisco, CA.
Comments